Zura Bio Limited
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $394.0M
- Price
- $4.09
- % Change (Daily % change from the live per-ticker quote feed.)
- +9.95%
- Volume
- 3.0M
About
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
Quick stats
Shares outstanding96.3M
Computed float55.1M
Float / shares57.2%
Cash runway (months)33.4
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001855644
Websitehttps://zurabio.com
AI Summary
AI-generated1/20
minorneutralother
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zura Bio granted inducement options to purchase 250,200 Class A shares to five newly hired employees on October 26, 2026.
The options carry a $3.56 exercise price equal to that day's close and vest over four years with a one-year cliff, granted outside the 2023 Equity Incentive Plan under Nasdaq Listing Rule 5635(c)(4).
This is a routine compensation disclosure with no bearing on the clinical-stage immunology pipeline, including lead candidate tibulizumab in Phase 2 studies.